What does this research mean for the field?

A chemotherapy-free strategy of initial mosunetuzumab followed by response-adapted polatuzumab vedotin and obinutuzumab yields high complete response rates and progression-free survival with limited toxicity in previously untreated indolent B-cell non-Hodgkin lymphoma. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 16, 2026Journal of Clinical Oncology

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

RLRyan C. LynchCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa CPChristina PohCity Of Hope National Medical Center MSMazyar ShadmanUniversity of Washington

Discussion

Member takes

Implication

Clinical trial reveals high complete response rates with a chemotherapy-free mosunetuzumab regimen in untreated indolent B-cell lymphoma, indicating a viable personalized frontline strategy.

Key Points

To evaluate the efficacy and safety of initial mosunetuzumab followed by response-adapted polatuzumab vedotin and obinutuzumab as a chemotherapy-free regimen for untreated indolent B-cell non-Hodgkin lymphoma.
Enrolled 42 previously untreated patients with follicular lymphoma (88%) or marginal zone lymphoma requiring therapy.
Patients received 8 cycles of mosunetuzumab monotherapy; individuals without a complete response on PET-CT subsequently received 6 cycles of polatuzumab vedotin and obinutuzumab.
End-of-treatment overall response rate was 100% and complete response rate was 86% (100% and 71%, respectively, for mosunetuzumab alone).
At a median follow-up of 34 months, 2-year progression-free survival reached 89% (95% CI, 80 to 100) and 2-year overall survival was 100%.
Grade 1 cytokine release syndrome occurred in 64% of participants, with none requiring tocilizumab.

Cite This Study

Lynch et al. (2026) studied this question.

synapsesocial.com/papers/6a8179cbf2fb91fc834ad2fd https://doi.org/10.1200/jco-25-02906

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial reveals high complete response rates with a chemotherapy-free mosunetuzumab regimen in untreated indolent B-cell lymphoma, indicating a viable personalized frontline strategy.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider